{"entity":{"id":"tgfb2","kind":"target","name":"TGFB2","aka":["transforming growth factor beta 2","Transforming growth factor beta-2 proprotein"],"tldr":"TGFB2 (Transforming growth factor beta-2 proprotein) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.","summary":"Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively. Required to maintain the Transforming growth factor beta-2 (TGF-beta-2) chain in a latent state during storage in extracellular matrix. Associates non-covalently with TGF-beta-2 and regulates its activation via interaction with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2.\n\nOpen Targets scores its association with cancer at 0.57 (direct and indirect evidence; datatypes clinical 0.65, literature 0.99, genetic association 0.59, somatic mutation 0.19, animal model 0.51).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:11768","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11768"},{"label":"UniProt P61812","url":"https://www.uniprot.org/uniprotkb/P61812/entry"},{"label":"NCBI Gene 7042","url":"https://www.ncbi.nlm.nih.gov/gene/7042"},{"label":"Ensembl ENSG00000092969","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000092969"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["mds"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.92; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"TGFB2","role":["drug-target","fusion-partner"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:11768","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11768","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P61812","url":"https://www.uniprot.org/uniprotkb/P61812/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000092969","url":"https://platform.opentargets.org/target/ENSG00000092969/associations","note":"association with cancer (MONDO_0004992) 0.57; per-cancer scores at or above 0.5: myelodysplastic syndrome 0.57 (GraphQL API, CC0)"}],"hgnc":"HGNC:11768","ensembl":"ENSG00000092969","uniprot":"P61812","entrez":"7042","biology":"Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively. Required to maintain the Transforming growth factor beta-2 (TGF-beta-2) chain in a latent state during storage in extracellular matrix. Associates non-covalently with TGF-beta-2 and regulates its activation via interaction with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2. Multifunctional protein that regulates various processes such as angiogenesis and heart development. Activation into mature form follows different steps: following cleavage of the proprotein in the Golgi apparatus, Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains remain non-covalently linked rendering TGF-beta-2 inactive during storage in extracellular matrix. At the same time, LAP chain interacts with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2 and maintain it in a latent state during storage in extracellular milieus. Location: Secreted, extracellular space, extracellular matrix; Secreted (UniProt). Locus 1q41 (HGNC).","whereFound":["Myelodysplastic syndromes / neoplasms: Open Targets association 0.57 with myelodysplastic syndrome (MONDO_0018881)"],"targetClass":"other","prevalence":[]},"route":"/targets/tgfb2/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}]}}